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Peptide transporter 2 (PEPT2) is a member of the proton-coupled oligopeptide transporter family, which
mediates the cellular uptake of oligopeptides and peptide-like drugs. Although PEPT2 is expressed in
many tissues, its expression in epidermal keratinocytes remains unclear. We investigated PEPT2
expression proﬁle and functional activity in keratinocytes. We conﬁrmed PEPT2 mRNA expression in
three keratinocyte lines (normal human epidermal keratinocytes (NHEKs), immortalized keratinocytes,
and malignant keratinocytes) by reverse transcription-polymerase chain reaction (RT-PCR) and quanti-
tative real-time RT-PCR. In contrast to PEPT1, PEPT2 expression in the three keratinocytes was similar or
higher than that in HepG2 cells, used as PEPT2-positive cells. Immunolocalization analysis using human
skin showed epidermal PEPT2 localization. We studied keratinocyte transport function by measuring the
oligopeptide content using liquid chromatography/tandem mass spectrometry. Glycylsarcosine uptake in
NHEKs was pH-dependent, suggesting that keratinocytes could absorb small peptides in the presence of
an inward Hþ gradient. We also performed a skin-permeability test of several oligopeptides using skin
substitute, suggesting that di- and tripeptides pass actively through the epidermis. In conclusion, PEPT2
is expressed in keratinocytes and involved in skin oligopeptide uptake.
© 2016 DHC corporation. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
In mammals, peptide transporter 1 (PEPT1) and peptide trans-
porter 2 (PEPT2) belong to the solute carrier 15 (SLC15) family,
comprising proton-coupled oligopeptide transporters (POTs)
involved in uptake of small peptides (dipeptides and tripeptides)
and peptide-like drugs across cytoplasmic membranes [1]. These
two prototypic POTs have been identiﬁed as SLC15A1 and SLC15A2,
respectively. PEPT1 is expressed primarily in intestinal epithelia
and also in the kidney [2,3]. PEPT2 is expressed primarily in the
kidney and is widely distributed in other tissues, except small in-
testine [4,5]. Immunolocalization studies have shown that PEPT1
and PEPT2 are localized at the brush border membranes of intes-
tinal and renal epithelial cells, respectively [6,7]. They have been
reported to be involved in dietary peptide absorption in the smallsevier Inc. This is an open access aintestine and peptide ﬁltration in the kidney.
PEPT1 can recognize a wide range of di- and tripeptides, but not
free amino acids or tetrapeptides, with various molecular size and
charges as potential substrates [1]. PEPT1 can also transport large
amounts of oligopeptides and two types have been characterized:
low-afﬁnity and high-capacity. In contrast, PEPT2 is characterized
by high-afﬁnity/low-capacity [8]. These differences in substrate
afﬁnity are thought to be caused by the different speciﬁcity of each
POT for a- or b-amino carbonyl structures of substrates [9].
With respect to nutrient absorption, functional analyses of
PEPT1 and PEPT2 have been performed mainly in small intestine
and kidney. Because PEPT2 is expressed in various tissues, several
studies have identiﬁed its physiological functions other than in
nutritional processes. PEPT2 has been reported to act as an efﬂux of
small peptides and peptide-like drugs from cerebrospinal ﬂuid into
the choroid plexus [10]. PEPT2 is expressed in astrocytes, ependy-
mal cells, and choroid plexus epithelial cells, and it is thought to
remove neuropeptide fragments broken down by peptidases
following their neuronal release [11]. Thus, growing interest hasrticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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peptide transporters. However, expression proﬁles and functional
activities of peptide transporters in skin remain unclear. In the
present study, we examined PEPT1 and PEPT2 mRNA expression in
human keratinocytes. After conﬁrming strong PEPT2 expression in
keratinocytes, we investigated the transporter that mediates the
uptake of oligopeptides, such as glycylsarcosine (GlySar).
2. Materials and methods
2.1. Materials
GlySar was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Custom-synthesized L-alanyl-4-hydroxy-L-proline (AlaHyp), L-
alanyl-4-hydroxy-L-prolyl-L-glycine (AlaHypGly), L-alanyl-4-
hydroxy-L-prolyl-L-alanyl-4-hydroxy-L-proline ([AlaHyp]2), and L-
norvaline-L-norvaline (NvaNva) were obtained from Genescript
(Piscataway, NJ, USA). All other chemicals were of the highest
commercially available grade.
2.2. Cell cultures and human skin
Normal human epidermal keratinocytes (NHEKs, newborn/
male, Thermo Fisher Scientiﬁc, Waltham, MA, USA) were main-
tained in keratinocyte growth medium consisting of Medium 154
and human keratinocyte growth supplement (both from Thermo
Fisher Scientiﬁc). Normal human dermal ﬁbroblasts (newborn/
male, Kurabo Industries, Osaka, Japan) were maintained in ﬁbro-
blast growth medium consisting of Medium 106 and low-serum
growth supplement (both from Thermo Fisher Scientiﬁc). Normal
human epidermal melanocytes (newborn/male, Thermo Fisher
Scientiﬁc) were maintained in melanocyte growth medium con-
sisting of Medium 254 and human melanocyte growth supplement
(both from Thermo Fisher Scientiﬁc). Three cell lines (A431, PSVK1,
and HepG2) were purchased from the Japanese Collection of
Research Bioresources (Osaka, Japan). A431 cells were cultured in
high-glucose Dulbecco’s modiﬁed Eagle’s medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS). PSVK1 cells were
grown in nutrient medium MCDB153 (Sigma) supplemented with
5-mg/ml insulin, 0.5-mg/ml hydrocortisone, 10-mg/ml transferrin,
0.1-mM phosphorylethanolamine, 0.1-mM ethanolamine, 10-ng/ml
epidermal growth factor, and 40-mg/ml bovine pituitary extract.
HepG2 cells were maintained in low-glucose DMEM supplemented
with 10% FBS. Caco-2 cells (obtained from RIKEN Cell Bank, Tsu-
kuba, Japan) were cultured in Eagle’s minimal essential medium
supplemented with 10% FBS and grown for 21 days for assessment
of transporter expression. All cells were grown in a humidiﬁed
incubator at 37 C in an atmosphere containing 5% CO2. The me-
dium was changed every other day and the cells were passaged
when they reached 80%e90% conﬂuency. NHEKs were not used
beyond passage 6. The medium was changed every day when cells
reached 50% conﬂuency. A skin substitute (EPI-606, Kurabo In-
dustries) was preliminarily incubated in EPI-100 assay medium
(Kurabo Industries) at 37 C with 5% CO2.
Human abdominal skin sample was purchased from Biopredic
International (Rennes, France). The donor was a 39-year-old
Caucasian woman. This human experiment was approved by and
followed the guidelines for the ethical use of human-origin organs
and tissues of KAC (Kyoto, Japan), an alliance partner for Biopredic
International.
2.3. Reverse transcription-polymerase chain reaction (RT-PCR) and
quantitative real-time RT-PCR (qPCR)
Total RNA was isolated from cultured cells using an RNeasyMini Kit (Qiagen, Mississauga, Canada), according to the manu-
facturer’s instructions. RNA was stored in RNase-free water at
80 C until reverse transcription. First-strand cDNA was syn-
thesized with 1 mg of total RNA using a PrimeScript® II 1st strand
cDNA Synthesis Kit (Takara Bio, Shiga, Japan), according to the
manufacturer’s instructions. For gene expression studies, the
cDNA was mixed with KOD Plus (Toyobo, Osaka, Japan) as a DNA
polymerase and gene-speciﬁc primers. The primers used were as
follows: human PEPT1, 50-GGTAAAGTGGCCAAGTGCAT-30 and 50-
CAAACAAGGCCCAGAACATT-30 for a 193-bp fragment; human
PEPT2, 50-TGACAGTGGTGGGAAATGAA-30 and 50-TCCCATCTTCAC-
GAATGACA-30 for a 204-bp fragment; and human GAPDH, 50-
GAGTCAACGGATTTGGTCGT-30 and 50-TTGATTTTGGAGG-
GATCTCG-30 for a 238-bp fragment. The PCR conditions on a
GeneAmp® PCR System 9700 (Applied Biosystems, Foster City,
CA, USA) were 30 cycles at 98 C for 10 s, 60 C for 5 s, and 72 C
for 15 s. PCR products were separated on a 2% agarose gel. For
qPCR, target-gene mRNA expression levels were measured using
an Applied Biosystems 7500 Real Time PCR System (Applied
Biosystems) with the following TaqMan® Gene Expression As-
says: PEPT1 (assay ID Hs00192639_m1); PEPT2 (assay ID
Hs01113665_m1); 18S (assay ID Hs99999901_s1). All reactions
were performed in triplicate. 18S was used as a housekeeping
gene for quantity normalization. The relative mRNA amounts
were calculated using the comparative CT method. The results
are presented as fold change of each mRNA in the other cells
relative to Caco-2 or HepG2 cells used as positive cells of PEPT1
or PEPT2, respectively.
2.4. Immunohistochemical analysis
For immunoﬂuorescence histochemistry of PEPT2, a sample of
human abdominal skin tissue was ﬁxed to 4% paraformaldehyde in
phosphate-buffered saline (PBS) at 4 C overnight. After rinsing
with PBS, the tissue was imbibed in 20% sucrose in PBS at 4 C
overnight and then embedded in Tissue Freezing Medium (Leica
Biosystems, Nussolch, Germany). Frozen tissues were cut in 7-mm
slices with a cryostat. Sections were rinsed with PBS and subse-
quently treated with 0.1% Triton-X 100 in PBS for 30 min at room
temperature. Nonspeciﬁc reactions were blocked by incubation of
sections in 3% horse serum in PBS for 30 min. A polyclonal rabbit
anti-PEPT2 antibody (Abcam, Cambridge, MA, USA) at a dilution of
1:100 in 1% bovine serum albumin (BSA) in PBS was applied
overnight at 4 C. After washing in PBS, sections were incubated
with Alexa Fluor 488 chicken anti-rabbit IgG (Thermo Fisher Sci-
entiﬁc) at a dilution of 1:400 in 1% BSA in PBS for 1 h at room
temperature. Following a rinse in PBS, sections were treatedwith 1-
mg/ml of 40,6-diamidino-2-phenylindole (DAPI) (Dojindo Labora-
tories, Kumamoto, Japan) in PBS for 3 min. After washing in PBS,
sections were mounted using Fluoromount plus (Diagnostic Bio-
Systems, Pleasanton, CA, USA). Fluorescence signals were examined
with a Leica confocal ﬂuorescence microscope (Leica Microsystems
Japan, Tokyo, Japan).
2.5. Uptake measurements
For the uptake studies, NHEKs were seeded at a density of
1.8  106 cells/dish on 100-mm plastic culture dishes. GlySar up-
take in cells was measured with uptake buffer whose composition
was 25-mM Mes/Tris (pH 6.5), 140-mM NaCl, 5.4-mM KCl, 1.8-mM
CaCl2, 0.8-mM MgSO4, and 5-mM glucose [12]. In experiments
where uptake buffers of different pH in the range of 6.5e8.5 were
used, two buffers were prepared, one containing 25-mM Mes/Tris
(pH 6.5) 140-mM NaCl, 5.4-mM KCl, 1.8-mM CaCl2, 0.8-mM
MgSO4, and 5-mM glucose and the other containing 25-mM
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mM MgSO4, and 5-mM glucose, and these buffers were mixed to
give the desired pH. The culture medium was removed from
dishes and the cells were washed twice with the uptake buffer.
Uptake was initiated by adding 10 ml of the uptake buffer con-
taining GlySar. Incubation was continued for the desired time,
after which uptake was terminated by uptake buffer removal,
followed by three washes with ice-cold uptake buffer. The cells
were then challenged with a hypotonic solution at 4 C and the
contents were collected as samples for subcellular GlySar content
determination. GlySar content in samples was determined by
liquid chromatography/tandem mass spectrometry (LC-MS/MS) as
described below. The restored samples were heated at 95 C for
10 min to inactivate peptidases.2.6. In vitro skin-permeability study
The skin permeability of oligopeptides was assessed using a
skin substitute (EPI-606), used after cultured skin piece removal
from a plastic insert with a knife. Each skin membrane was
mounted in a Franz-type diffusion cell (effective diffusion area
0.64 cm2). Then, 0.5 ml of aqueous solution containing 5% of each
oligopeptide was applied to the stratum corneum side and 5 ml of
PBS was applied to the suprabasal side. The skin-permeability test
was performed at 4 C or 37 C over 6 h using the skin substitute,
whereas the receiver solution was continuously stirred with a
magnetic stirrer; 0.2-ml samples were periodically obtained from
the suprabasal side compartment, and an identical volume of the
same solvent was added to keep the volume constant. The content
of each oligopeptide in leakage samples was determined using LC-
MS/MS as described below.Fig. 1. PEPT1 and PEPT2 mRNA expression proﬁles in keratinocytes. (A), Total RNA samples
keratinocytes (A431), were analyzed by RT-PCR using speciﬁc primers. The human intestinal
PEPT1 and PEPT2, respectively. (B), RT-PCR analyses of PEPT1 and PEPT2 in three different lot
and A431. (E,F), qPCR analyses of PEPT1 and PEPT2 in normal melanocytes, ﬁbroblasts, and k
relative to Caco-2 or HepG2 cells used as positive cells of PEPT1 or PEPT2, respectively. Val2.7. GlySar measurement using LC-MS/MS
GlySar was directly detected and quantiﬁed by LC-MS/MS using
selected ion monitoring in the positive-ion electron capture mode.
MS was performed on an API 2000 tandem mass spectrometer (AB
SCIEX, Tokyo, Japan) equipped with a standard API electrospray
ionization source and interfaced with an Agilent 1100 HPLC (Agi-
lent Technologies, Santa Clara, CA, USA). Samples were injected
onto a Develosil ODS-HG-3 column (2  250-mm, Nomura Chem-
ical, Aichi, Japan) at a ﬂow rate of 0.15 ml/min. The separation was
performed with a two-pump gradient. Solvent A was 0.1% formic
acid and solvent B was acetonitrile. The gradient program was as
follows; 0 min, A 95%; 5 min, A 95%; 10 min, A 0%; 20 min, A 0%.
Analyses were monitored in positive-ion mode using the API ion
source at 400 C and with multiple reaction monitoring (MRM).
Nitrogen was used as a curtain (setting 40), nebulizing (setting 15),
and collision (setting 7) gas. NvaNva was added to samples at a 1-
mg/ml concentration as an internal standard. GlySar and NvaNva
were eluted at 5 and 8 min, respectively, under these conditions.
The following MRM transitions were selected: (m/z, Q1/Q3) of
GlySar (m/z, 147.0/ 90.0), NvaNva (m/z, 217.1/ 72.2).
2.8. Hyp-containing peptide measurement using LC-MS/MS
Each sample containing peptides was hydrolyzed by treatment
with 6-N HCl at 110 C for 24 h and analyzed as Hyp by LC-MS/MS.
Samples were injected onto an Intrada Amino Acid column
(3 100 mm, Imtakt, Kyoto, Japan) at a ﬂow rate of 0.6 ml/min. The
separation was performed with a two-pump gradient. Solvent A
was acetonitrile/tetrahydrofuran/25-mM ammonium formate/for-
mic acid (9/75/16/0.3, v/v/v/v) and solvent B was acetonitrile/100-
mM ammonium formate (20/80, v/v). The gradient program wasof normal keratinocytes (NHEKs), immortalized keratinocytes (PSVK1), and malignant
cell line Caco-2 and the human hepatoma cell line HepG2 were used as positive cells of
s of NHEKs were conducted. (C,D), qPCR analyses of PEPT1 and PEPT2 in NHEKs, PSVK1,
eratinocytes. The results are presented as fold change of each mRNA in the other cells
ues represent the mean ± SE of triplicate determinations (N.D., not detectable).
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0%. Analyses were monitored in positive-ion mode using the API
ion source at 400 C, and MRM. Nitrogen was used as a curtain
(setting 40), nebulizing (setting 15), and collision (setting 7) gas.
NvaNva was added to samples at a 1-mg/ml concentration as an
internal standard and analyzed as Nva after acid hydrolysis. Hyp
and Nva were eluted at 7 and 8 min, respectively, under these
conditions. The following MRM transitions were selected: (m/z,
Q1/Q3) of Hyp (m/z, 132.1/ 86.1), Nva (m/z, 90.1/ 44.1).
2.9. Statistical analyses
Data are expressed as mean ± SE from at least three indepen-
dent experiments. Statistical analyses were performed using the
TukeyeKramer test.
3. Results and discussion
In this study, we investigated PEPT1 and PEPT2 gene expression
proﬁles in epidermal keratinocytes. Initially, we examined PEPT1
and PEPT2 expressions in three keratinocytes: normal keratino-
cytes (NHEKs), immortalized keratinocytes (PSVK1), and malig-
nant keratinocytes (A431). The human intestinal cell line Caco-2
and the human hepatoma cell line HepG2 were used as the pos-
itive cells of PEPT1 and PEPT2, respectively. PCR detection
conﬁrmed that both PEPT1 and PEPT2 are expressed in all kerati-
nocytes (Fig. 1A and B). The speciﬁcity of PCR detection was
conﬁrmed by sequencing analysis of the detected mRNA-derived
PCR products and the DNA sequences of the PCR products wereFig. 2. Immunoﬂuorescence localization of PEPT2 in human skin tissue. (AeC), Frozen sectio
are also shown. White dotted lines represent basal membrane. The area near the basal layer i
corneum and dermis (white arrows). Sc: stratum corneum. E: epidermis. D: dermis. Bars, 2100% identical to reference sequences in Genbank (data not
shown). The expression levels of PEPT1 and PEPT2 were evaluated
by qPCR. Whereas all three keratinocytes showed very low PEPT1
expression compared with Caco-2 cells (Fig. 1C), PEPT2 expres-
sions in all three keratinocytes were higher than or nearly equal to
that in HepG2 cells (Fig. 1D), suggesting that PEPT2 is expressed
mainly in keratinocytes. As other skin cell types, melanocytes and
dermal ﬁbroblasts showed no or much lower PEPT1 and PEPT2
mRNA expression than NHEKs (Fig. 1E and F). Immunolocalization
analysis of human skin revealed PEPT2-positive staining in the
epidermis (Fig. 2), with the area closer to basal membrane
showing the strongest staining (red arrows in Fig. 2B and C).
Positive staining was absent in the dermis or stratum corneum
(white arrows in Fig. 2B and C). Overall, PEPT2 was clearly
expressed in epidermal keratinocytes, which were more common
than other skin cells, such as dermal ﬁbroblasts.
PEPT1 and PEPT2 function in di- and tripeptide absorption. To
investigate peptide transport function in keratinocytes, we
measured the uptake of GlySar that is a well-known dipeptide as a
transported substrate of PEPT1/2. After exposure to GlySar, its up-
take was calculated by GlySar content measurement in perme-
ability samples using LC-MS/MS with NvaNva as an internal
standard (Fig. 3A). Fig. 3B and C shows the time course and con-
centration dependence, respectively, of GlySar uptake by NHEKs.
GlySar uptake increased with incubation time and concentration of
GlySar. The pH dependence of GlySar uptake was further examined
in the pH range of 6.5e8.5 in NHEKs. As shown in Fig. 3D, GlySar
uptake showed a clear pH dependency with a pH optimum at 6.5,
and decreased at higher pHs. These results suggest that epidermalns were stained for PEPT2 (green) and DNA (blue). (D), Corresponding Nomarski images
n the epidermis is stained for PEPT2 (red arrows), whereas stain is absent in the stratum
0 mm.
Fig. 3. Time course and concentration/pH dependence of GlySar uptake in NHEKs. (A), LC-MS/MS proﬁle for GlySar uptake measurement in NHEKs cultured without (left) or with
GlySar (middle). NvaNva was added to samples at a 1-mg/ml concentration as an internal standard (right). GlySar and NvaNva were monitored in MRM mode for m/z ¼ 147/ 90
and m/z ¼ 217/ 72, respectively. (B) Inﬂux of GlySar (1 mg/ml) into NHEKs was measured over 60 min at pH 6.5 for a time-course study. (C), Inﬂux of GlySar (0.04e5 mg/ml) was
measured at pH 6.5 with an incubation time of 30 min for a concentration-dependence study. (D) Inﬂux of GlySar (1 mg/ml) was measured at pH 6.5e8.5 with an incubation time of
30 min for a pH-dependence study. Values represent the mean ± SE of triplicate determinations.
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presence of an inwardly directed Hþ gradient.
To investigate the peptide absorptive behaviors of keratinocytes
at the tissue level, a skin-permeability test for peptides was per-
formed using a Franz cell with a skin substitute (Fig. 4A), which is
reconstructed as a human epidermis alone. As shown in Fig. 4B, the
transdermal amount of GlySar increased over 6 h. The skin-
permeability test was also performed using AlaHyp, which has
been identiﬁed to be as one of food-derived collagen peptides
[13,14]. POTs in the small intestine are thought to be involved in
intestinal absorption of such collagen peptides after ingestion of
dietary gelatin hydrolysate [15]. The permeability was calculated by
Hyp content measurement after acid hydrolysis of the permeability
sample (as described in “Materials and methods”). Linear pene-
tration of AlaHyp was detected as well as of GlySar (Fig. 4C), sug-
gesting that dipeptides (e.g., AlaHyp) could be transdermally
absorbed. To determine peptide sizes required for skin perme-
ability, a skin-permeability test was conducted using peptides of
different sizes. Both di- and tripeptide penetrated skin (Fig. 4D),
whereas tetrapeptide did not. Among the three oligopeptides
tested, dipeptide had the highest skin penetration.
Co-treatment with GlySar inhibited transdermal AlaHyp ab-
sorption (Fig. 4E). The transdermal amounts of AlaHyp decreased
by 79.5% and 80.8% in the presence of 5% and 20% of GlySar,
respectively. This result suggests that AlaHyp and GlySar share a
common transporting route. In addition, the transdermal amounts
of AlaHyp and GlySar decreased by 76.2% and 64.4%, respectively,
when the temperature was decreased to 4 C (Fig. 4F), suggesting
that the majority of these oligopeptides pass actively through the
epidermis.
The epidermis is composedmainly of four layers: the basal layer,
spinous layer, granular layer, and stratum corneum. Differentiationinto the keratinocytes of each layer, originating from immature
stem cells located in the basal membrane, occurs along the basal
layerestratum corneum axis. Our immunolocalization analysis
using human skin showed the highest PEPT2 expression closer to
the basal layer in the epidermis (red arrows in Fig. 2B and C). This
tissue-speciﬁc PEPT2 localization in the epidermis is presumed to
conserve peptide-bound amino nitrogen in amanner similar to that
at brush-border membranes of renal epithelial cells [1], serving for
keratinocyte differentiation. Immune-positive staining was also
detected in the other suprabasal layers. This result suggests that
PEPT2 in the epidermis mediates oligopeptide transport from the
basal to the other layers. PEPT2 mediates the one-way intracellular
oligopeptide uptake as an active transporter energized by a trans-
membrane electrochemical Hþ gradient, implying the presence of
efﬂux properties of peptide transporter(s) in the epidermis. Several
efﬂux properties of peptide transporters are present in the small
intestine [16,17] and are expected to be found in the epidermis.
In contrast to keratinocytes, dermal ﬁbroblasts andmelanocytes
expressed no or low levels of PEPT1 and PEPT2. Recently, pepti-
deehistidine transporters 1 (PHT1, encoded by SLC15A4) and PHT2
(encoded by SLC15A3) have been identiﬁed as new SLC15 family
members [18,19]. While these two POTs have been reported to
transport histidine intracellularly as well as oligopeptides, much
less is known about their localizations and structure/function. We
investigated the expressions of these two POTs in keratinocytes,
ﬁbroblasts, and melanocytes. PHT1 was more highly expressed in
melanocytes than in the other cells (Supplementary Fig. 1A). In
contrast to PHT1 expression, PHT2 expression in ﬁbroblasts was
markedly higher than that in the other cells (Supplementary
Fig. 1B). In view of these differences in POT expression, we specu-
late that these skin cells individually regulate peptide transport by
activating preferred POTs. Thus, to identify the functions of POTs in
Fig. 4. Permeation of GlySar and Hyp-containing peptides through a skin substitute. (A), The skin permeation of oligopeptides was performed using a Franz cell with a skin
substitute. (B,C), The time course of GlySar or AlaHyp permeation was measured at 37 C over 6 h. (D), A skin-permeability test of Hyp-containing peptides was conducted using
peptides of three different sizes: AlaHyp, AlaHypGly, and [AlaHyp]2. Aqueous solution containing 5% of each peptide was applied to the stratum corneum side of a skin substitute.
After 6 h of incubation, each sample containing peptides was hydrolyzed by treatment with 6-N HCl at 110 C for 24 h and analyzed as Hyp by LC-MS/MS (see “Materials and
methods”). (E), The competitive effect of GlySar on AlaHyp permeation through a skin substitute. Aqueous solution containing 5% AlaHyp without or with 5%e20% GlySar was
applied to the stratum corneum side of a skin substitute. AlaHyp permeation was measured after 6 h of incubation. (F), The effect of temperature on GlySar and AlaHyp permeation
through a skin substitute. The skin permeation test was performed at 4 or 37 C with 6 h of incubation. Values represent the mean ± SE of triplicate determinations [**p < 0.01
versus 5% AlaHyp group, yyp < 0.01 versus 37 C group corresponding to each peptide (TukeyeKramer test)].
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Recent studies have shown that oligopeptides play physiological
roles in wound healing and skin tissue repair [20,21]. The present
results raise the possibility that PEPT2 expressed predominantly in
keratinocytes is involved in transcellular transport of oligopeptides
and peptide-like drugs. Thus, some oligopeptides may act as cyto-
plasmic oligopeptide signals following cell entry via POTs, such as
PEPT2. Additionally, di- and tripeptides are expected to penetrate
skin, contributing to development of topical peptide-like drugs.
In summary, the proton-coupled oligopeptide transporter PEPT2
is expressed in epithelial keratinocytes and serves to absorb
oligopeptides.
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